Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMB-05X in ctDNA(+) Colorectal Cancer After Curative-intent Treatment
NCT06617858Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABM-05X in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Circulating tumor DNA clearance rate at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
ABM-05X
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06617858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617858.